CRISPR/Cas9 Gene Insertion via AAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for treating monogenic diseases and lysosomal storage disorders face challenges in achieving efficient and specific genome editing, particularly in achieving sustained therapeutic benefits with minimal off-target effects and vector-associated risks.
Innovation Solution
The use of the CRISPR/Cas system, specifically with SaCas9 and guide RNAs, delivered via AAV vectors, for targeted insertion of therapeutic genes into safe harbor loci like the albumin locus, enabling homology-directed repair and promoting the expression of therapeutic proteins with minimal off-target effects and reduced vector doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If CRISPR/Cas system is used for genome editing, then targeted insertion of therapeutic genes is achieved, but off-target effects and vector-associated risks occur
Solution Approach 1:
The patent employs safe harbor loci (such as AAVS1, HPRT, CCR5, albumin locus) that are specifically selected for their unique genomic characteristics - these locations have been validated to permit precise integration without disrupting essential genes or regulatory elements. The CRISPR guide RNAs are designed to target specific sequences within these safe harbor loci, ensuring that the therapeutic gene insertion occurs only at the intended location while avoiding off-target effects in other genomic regions.
Solution Approach 2:
The patent utilizes homology-directed repair (HDR) as an intermediary mechanism between the CRISPR/Cas-induced double-strand break and the final therapeutic gene integration. By providing homology arms that match the safe harbor locus sequence, the HDR pathway mediates precise insertion of the therapeutic construct at the targeted location, thereby achieving manufacturing precision while minimizing harmful off-target effects.
2Reliability
If viral vectors are used for gene delivery, then transgene integration is achieved, but vector-associated risks increase
Solution Approach 1:
The patent divides the gene delivery system into separate functional components: (1) CRISPR/Cas system for creating targeted breaks and facilitating integration, (2) viral vectors for delivering the therapeutic construct, and (3) homology arms for guiding precise integration. This segmentation allows each component to be optimized independently - the viral vectors can be designed for efficient delivery while the CRISPR system provides the targeting precision, thereby reducing vector-associated risks while maintaining integration reliability.
Solution Approach 2:
The patent employs synthetic homology arms that are copied sequences matching the safe harbor locus. These homology arms serve as templates that guide the integration process, allowing the therapeutic construct to be precisely inserted without requiring the viral vector to carry complex targeting information. This copying approach simplifies the vector design and reduces associated risks while maintaining reliable integration.
3Productivity
If high vector doses are administered, then therapeutic benefit is achieved, but safety risks increase
Solution Approach 1:
The patent changes the key parameter of integration precision by targeting safe harbor loci with validated CRISPR guide RNAs. This parameter change enables efficient therapeutic gene integration at the correct location, thereby achieving therapeutic benefit at lower vector doses. The use of homology-directed repair further enhances this efficiency, allowing precise integration without requiring high doses of viral vector, thus reducing safety risks associated with high-dose administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant increases in therapeutic enzyme activities, such as IDUA in MPS I mice, with low off-target events and reduced vector doses, offering a promising strategy for treating lysosomal storage disorders and other genetic diseases with minimized risks and costs.
Implementation Method 1
the transgene construct is inserted by either homology directed repair (HDR) or by end capture during non-homologous end joining (NHEJ) driven processes
Implementation Method 2
Nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or nuclease systems such as the CRISPR/Cas system (utilizing an engineered guide RNA), are specific for targeted genes
Implementation Method 3
delivery of one or more genes encoding proteins using CRISPR/Cas, delivered via one or more vectors such as plasmids or viral vectors, including but not limited to lentivirus vectors, adenovirus vectors, adeno-associated virus (AAV) vectors
Data Source
AI summary
Compositions and methods for Cas-based ex vivo and in vivo gene therapy applications are provided.